Final results from the phase Ib/II study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in patients with relapsed or progressive multiple myeloma.
Michael Wang
Honoraria - Celgene
Research Funding - Celgene; Millennium; Novartis; Onyx
Thomas Martin
Consultant or Advisory Role - Onyx
Honoraria - Celgene
Research Funding - Onyx
William Bensinger
Consultant or Advisory Role - Onyx
Research Funding - Onyx
Melissa Alsina
Consultant or Advisory Role - Millennium; Novartis
Research Funding - Allergan; Millennium
David Samuel DiCapua Siegel
Consultant or Advisory Role - Celgene; Millennium; Onyx
Honoraria - Celgene; Millennium
Edward Kavalerchik
Employment or Leadership Position - Onyx
Ruben Niesvizky
Honoraria - Onyx